Dr. Daniel A. Erlanson Carmot Therapeutics, Inc., USA

Daniel A. Erlanson has practiced fragment-based lead discovery since 1998. He previously developed Tethering at Sunesis Pharmaceuticals and is currently developing Chemotype Evolution at Carmot Therapeutics, which he co-founded. He earned his BA in chemistry from Carleton College, his PhD in chemistry from Harvard University, and did postdoctoral work at... read moreGenentech.